| 28-Nov-2025 |
Press Release Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock (28-Nov-2025, 9:20 AM Globe Newswire) |
|
|
|
|
|
+38.7% |
|
|
|
|
|
|
|
|
|
|
| 24-Nov-2025 |
Press Releases Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients (21-Nov-2025, 12:35 PM Globe Newswire) Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data (24-Nov-2025, 7:00 AM Globe Newswire) |
|
|
|
|
|
+45.3% |
|
|
|
|
|
|
|
|
|
|
| 6-May-2025 |
Press Releases Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 (6-May-2025, 7:03 AM Globe Newswire) Pasithea Therapeutics Announces Pricing of $5 Million Public Offering (6-May-2025, 11:10 AM Globe Newswire) |
|
|
|
|
|
+7.0% |
|
|
|
|
|
|
|
|
|
|
| 10-Apr-2025 |
Press Release Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (10-Apr-2025, 7:02 AM Globe Newswire) |
|
|
|
|
|
+46.8% |
|
|
|
|
|
|
|
|
|
|
| 5-Feb-2025 |
Press Release Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (5-Feb-2025, 6:59 AM Globe Newswire) |
|
|
|
|
|
+31.7% |
|
|
|
|
|
|
|
|
|
|
| 26-Sep-2024 |
Press Releases Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (26-Sep-2024, 7:02 AM Globe Newswire) Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules (26-Sep-2024, 6:44 PM Globe Newswire) |
|
|
|
|
|
+52.1% |
|
|
|
|
|
|
|
|
|
|
| 11-Dec-2023 |
Press Release Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models (11-Dec-2023, 8:01 AM Globe Newswire) |
|
|
|
|
|
+47.4% |
|
|
|
|
|
|
|
|
|
|
| 27-Nov-2023 |
|
|
|
|
|
|
+11.7% |
|
|
|
|
|
|
|
|
|
|
| 8-Nov-2023 |
|
|
|
|
|
|
+5.0% |
|
|
|
|
|
|
|
|
|
|
| 25-Sep-2023 |
|
|
|
|
|
|
+0.2% |
|
|
|
|
|
|
|
|
|
|
| 20-Jul-2023 |
Press Releases Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc. (20-Jul-2023, 8:40 AM Globe Newswire) Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash (20-Jul-2023, 8:43 AM Globe Newswire) |
|
|
|
|
|
+25.9% |
|
|
|
|
|
|
|
|
|
|
| 5-Jun-2023 |
Press Release Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp. (5-Jun-2023, 9:00 AM Globe Newswire) |
|
|
|
|
|
+25.0% |
|
|
|
|
|
|
|
|
|
|
| Simple Average Returns - 12 Largest Positive Opening Gaps |
| Avg Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Positive Occurrences |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Negative Occurrences |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Absolute Average Returns - 12 Largest Positive Opening Gaps |
| Abs Avg Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Max Abs Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Min Abs Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Median, Minimum, and Maximum Returns - 12 Largest Positive Opening Gaps |
| Median Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Max Positive Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Max Negative Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|